← Research library

Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients

Comparison in people · 2022

What was studied
48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
Main finding
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.

Moderate disease · duration · 14 ± 1.9 vs 16 ± 2.2 days · Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.

Reported findings and study design

Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.

Population or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.

Dose, route and schedule

Moderate disease: Vladonix one capsule twice daily during illness with intranasal interferon alfa-2b and Roncoleukin (500,000 IU for 6–8 days). Acute mild disease received interferon and Roncoleukin without Vladonix. The post-COVID sections describe Vladonix for 10 or 30 days alongside Roncoleukin. Capsule peptide mass is unspecified.

Protocol source ↗ · Original journal PDF, methods and Table 1

Results · Original journal PDF, methods and Table 1
MeasureResultComparison, timing and statistics
Moderate disease · duration14 ± 1.9 vs 16 ± 2.2 daysAdjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
Moderate disease · post-COVID symptoms3/12 vs 7/12Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days.
Worsening and reported adverse effectsNo cases reportedNo group-level adverse-event table or systematic assessment method is provided.
Table 1 · illness duration and post-COVID cases
Table 1 · illness duration and post-COVID cases
GroupnIllness (days)Post-COVID casesRecovery (days)
Mild · interferon + IL-2128 ± 1.20—
Mild · usual care1210 ± 1.8128
Moderate · Vladonix + interferon + IL-21214 ± 1.9332.2
Moderate · usual care1216 ± 2.2736.2

Table 1 means are used for acute illness. For moderate post-COVID recovery the prose gives ±4.5 and ±4.1 days, respectively. The corresponding table uncertainty fields are malformed.

The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.

Source for these results ↗ · Reviewed 2026-11-13

Study limitations and source details

Study limitations

  • Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone.
  • The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.

Source details

Original journal article

Original journal PDF, methods and Table 1

Sources checked

Added to the library

Citation

Human comparative studyFull text available

N. Serikov, A. Zinatollayeva, Z. Karimova, N. K. Kudaibergenova, G. Zh. Abdrakhmanova, D. B. Kozubaeva, F. F. Yagofarov. Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients Terapevt. 2022(4):34–39

Study source ↗ · DOI 10.33920/MED-12-2204-04 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards